feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouUnited StatesUnited States
You
bookmarksYour BookmarkshashtagYour Topics
Trending
Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2026 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Business and Economy / Wells Fargo Dims Outlook, Yet EMN Boosts Shareholder Payout

Wells Fargo Dims Outlook, Yet EMN Boosts Shareholder Payout

24 Dec, 2025

•

Summary

  • Eastman Chemical's dividend was raised for the 16th consecutive year.
  • Wells Fargo downgraded Eastman Chemical due to sector-wide 'trough-like conditions'.
  • The company's dividend increased to $0.84 per share, effective January 8, 2026.
Wells Fargo Dims Outlook, Yet EMN Boosts Shareholder Payout

Eastman Chemical Company (EMN) has announced a modest increase in its quarterly dividend, raising it to $0.84 per share from $0.83. This dividend, scheduled for payment on January 8, 2026, to shareholders of record as of December 15, 2025, represents the 16th consecutive year the company has enhanced its shareholder payout. This action underscores the board's confidence in the company's ability to generate consistent earnings and maintain strong cash flow, even amid a difficult operating environment.

However, this positive shareholder update followed a significant analyst downgrade. On December 19, Wells Fargo revised its rating for Eastman Chemical to Equal Weight from Overweight, maintaining a $70 price target. This decision was part of a broader reassessment of the chemicals sector, with Wells Fargo downgrading four companies due to industry checks indicating "trough-like conditions" that may persist into the first half of 2026.

trending

Qualcomm stock falls on shortages

trending

HAL shares tumble after AMCA

trending

Suzlon Energy Q3 results up

trending

Cognizant profit rises 18.7%

trending

JSW Cement Q3 profit rises

trending

Trent share price cautious outlook

trending

Pakistan India T20 boycott

trending

Savannah Guthrie pleads for mother

trending

Mrunal Thakur wedding rumours

The analyst's concerns stem from a muted recovery in China and weak housing markets in the US and Europe, factors that continue to pressure the sector. While interest rate cuts might provide eventual support, Wells Fargo anticipates that meaningful catalysts for valuation recoveries are still several quarters away, leaving near-term visibility limited for the industry.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
Wells Fargo downgraded Eastman Chemical due to concerns about 'trough-like conditions' in the chemicals sector, citing slow recovery in China and weak housing markets.
Eastman Chemical's new quarterly dividend is $0.84 per share, an increase from the previous $0.83 per share.
Eastman Chemical has increased its quarterly dividend for 16 consecutive years.

Read more news on

Business and Economyside-arrow

You may also like

Sun Pharma Eyes Strategic M&A for Global Growth

1 Feb • 29 reads

article image

Sun Pharma Q3 Profits Soar 16% on Strong Revenue Growth

31 Jan • 24 reads

article image

Sun Pharma Eyes Organon in $10-14B Mega-Deal

20 Jan • 113 reads

article image

Teva Stock Soars 45%, But Are Better Buys Lurking?

15 Dec, 2025 • 291 reads

article image

Commodore Capital Bets Big on Amylyx Pharmaceuticals

5 Dec, 2025 • 147 reads

article image